Quantified Postsurgical Small Cell Size CTCs and EpCAM+ Circulating Tumor Stem Cells with Cytogenetic Abnormalities in Hepatocellular Carcinoma Patients Determine Cancer Relapse.

Liang Wang,Yilin Li,Jing Xu,Aiqun Zhang,Xuedong Wang,Rui Tang,Xinjing Zhang,Hongfang Yin,Manting Liu,Daisy Dandan Wang,Peter Ping Lin,Lin Shen,Jiahong Dong

DOI: https://doi.org/10.1016/j.canlet.2017.10.004

IF: 9.756

2018-01-01

Cancer Letters

Abstract:Detection of hepatocellular carcinoma circulating tumor cells performed with conventional strategies, is significantly limited due to inherently heterogeneous and dynamic expression of EpCAM, as well as degradation of cytokeratins during epithelial-to-mesenchymal transition, which inevitably lead to non negligible false negative detection of such "uncapturable and invisible" CTCs. A novel SE-iFISH strategy, improved for detection of HCC CTCs in this study, was applied to comprehensively detect, in situ phenotypically and karyotypically characterize hepatocellular and cholangiocarcinoma CTCs (CD45(-)/CD31(-)) in patients subjected to surgical resection. Clinical significance of diverse subtypes of CTC was systematically investigated. Existence of small cell size CFCs (<= 5 pun of WBCs) with cytogenetic abnormality of aneuploid chromosome 8, which constituted majority of the detected CFCs in HCC patients, was demonstrated for the first time. The stemness marker EpCAM(+) aneuploid circulating tumor stem cells (CTSCs), and EpCAM small CFCs with trisomy 8, promote tumor growth. Postsurgical quantity of small triploid CTCs (>= 5 cells/6 ml blood), multiploid (>= pentasomy 8) CTSCs or CTM (either one >= 1) significantly correlated to HCC patients' poor prognosis, indicating that detection of those specific subtypes of CFCs and CTSCs in post-operative patients help predict neoplasm recurrence. (C) 2017 The Authors. Published by Elsevier B.V.